Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 9/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | P4HB | P07237 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gtx-758 SCHEMBL29420202 | 0.95 | ESR1 (1.00) | ESR1ESR2SNCAKDM4ELMNA | |
| Gtx-758 SCHEMBL2112794 | 0.95 | ESR1 (1.00) | ESR1ESR2SNCAKDM4ELMNA | |
| SCHEMBL2112708 | 0.94 | ESR1 (1.00) | ESR1ESR2SNCAKDM4ELMNA | |
| SCHEMBL12318272 | 0.93 | ESR1 (0.86) | ESR1ESR2SNCAKDM4ELMNA | |
| SCHEMBL2114738 | 0.87 | ESR1 (0.77) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL2113690 | 0.84 | ESR1 (0.73) | ESR1ESR2KDM4EHSD17B10 | |
| SCHEMBL10116906 | 0.84 | ESR1 (0.72) | ESR1ESR2 | |
| SCHEMBL10116875 | 0.80 | ESR1 (0.74) | ESR1ESR2HSD17B1HSD17B2HSP90AA1 | |
| SCHEMBL15491997 | 0.80 | ESR1 (0.67) | ESR1ESR2KDM4ELMNAHSD17B10 | |
| SCHEMBL2112286 | 0.80 | ESR1 (0.67) | ESR1ESR2HSD17B1HSD17B2HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624161-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9427418-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2012-03-29 | — | — | US | disclosed |
| WO-2011106317-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010096801-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077845-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GNRHR, LHCGR, SHBG | ESR1 21/4885ESR2 15/4885SNCA 4313/4885 |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | ESR1 7/4885ESR2 3/4885SNCA 4398/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SNCA 3222/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SNCA 3222/4885 |
| US-20100267773-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | SHBG, GNRHR, FSHR | ESR1 10/4885ESR2 9/4885SNCA 4796/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | ESR1 5/4885ESR2 3/4885SNCA 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.